Hypertension and Depression and Their Treatment *

Boura A. L. A. Green A. F. (1963). Adrenergic neurone blockade and other acute effects caused by N-benzyl-N'N”-dimenthyl-guanidine and its ortho-chloro derivatives. British Journal of Pharmacology 20: 36.

Bryant J. M. Schvartz N. Torosdag S. Fertig H. Fletcher L. Jr. Schwartz M. S. Quan R. B. (1963). Long term antihypertensive effect of pargyline HCI with and without diuretic sulfonamides. Annals of the New York Academy of Sciences, 107: 1923.

Davis D. Lamberti J. Ajans Z. A. (1969). Crying in depression. British Journal of Psychiatry, 115: 597.

Doyle A. E. Smirk F. H. (1954). Hypotensive action of reserpine. Lancet, 1: 1096.

Freis E. D. (1954). Mental depression in hypertensive patients treated for long periods with large doses of reserpine. New England Journal of Medicine, 251: 1006.

Fullerton A. G. Morton-Jenkins D. (1963). Methyldopa and depression. British Medical Journal, 1: 539.

Gillespie L. Oates J. A. Crout J. R. Sjoerdsma A. (1962). Clinical and chemical studies with a-methyl-dopa in patients with hypertension. Circulation, 25: 281.

Gillette J. R. (1965). Drug toxicity as a result of interference with physiological central mechanisms. Annals of the New York Academy of Sciences, 123: 42.

Gokhale S. D. Gulati O. D. Udwadia B. P. (1966). Antagonism of the adrenergic neurons blocking action of guanethidine by certain antidepressant and antihistamine drugs. Archives Internationales de Pharmacodinamie et de Therapie, 160: 321.

Hamilton M. (1968). Some aspects of the long-term treatment of severe hypertension with methyldopa. Post-graduate Medical Journal 44: 66.

Howwitz D. Pettinger W. A. Orvis H. Thomas R. E. Sjoerdsma A. (1967). Effects of methyldopa in fifty hypertensive patients. Clinical Pharmacology and Therapeutics, 8: 224.

Hughes I. E. (1968). Acute actions of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155) in the rat. Australian Journal of Experimental Biology and Medical Sciences, 46: 747.

Iisalo E. Laurila S. (1967). A clinical trial with a new antihypertensive drug, ST-155 (CatapresenR). Current Therapeutic Research, 9: 358.

Johnson P. Kitchin A. H. Lowther C. P. Turner R. W. D. (1966). Treatment of hypertension with methyldopa. British Medical Journal, 1: 133.

Kellett R. J. Hamilton M. (1970). The treatment of benign hypertension with clonidine. Scottish Medical Journal, 15: 137.

Kelliher R. J. (1970). Central hypotensive activity of dl- and d-propranolol. Journal of Pharmaceutical Sciences, 59: 1276.

Klerman G. L. Cole J. O. (1965). Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacological Review, 17: 101.

Lader M. H. (1970). Physical and physiological aspects of anxiety and depression. British Journal of Clinical Practice, 24: 35.

Lauwers P. Verstraete M. Jooseens J. V. (1963). Methyldopa in the treatment of hypertension. British Medical Journal, 1: 295.

Leishman A. W. D. Matthews H. L. Smith A. J. (1963). Antagonism of guanethidine by imipramine. Lancet, 1: 112.

Leszkovsky G. Tardos L. (1965). Some effects of propranolol on the central nervous system. Journal of Pharmacy and Pharmocology, 17: 518.

Locket S. (1955). Oral preparations of rauwolfia serpentina in treatment of essential hypertension. British Medical Journal, 1: 809.

Magus R. D. Long J. P. (1968). Mechanism of hypotensive action of 2-(2-6-dichlorophenyl-amino)-2-imidazoline hydrochloride (ST-155) in the cat. Journal of Pharmaceutical Sciences, 57: 594.

Marks I. M. (1970). Modes of clinical presentation of patients with anxiety and depression. British Journal of Clinical Practice, 24: 67.

Maxwell R. A. Plummer A. J. Schneider F. Povalski H. Daniel A. I. (1960). Pharmacology of [2-(octahydro-l-azocinyl)-ethyl]-guanidine sulphate (SU05864). Journal of Pharmacology and Experimental Therapy, 128: 22.

Miller H. (1967). Depression. British Medical Journal, 1: 257.

Mitchell J. R. Cavanaugh J. H. Arias L. Oates J. A. (1970). Guanethidine and related agents III Antagonism by drugs which inhibit the norepinephrine pump in man. Journal of Clinical Investigations, 49: 1596.

Moe R. A. Bates H. M. Palkoski Z. M. Banziger R. (1964). Cardiovascular effects of 3,4-dihydro-2(IH) isoquinoline carboxamidine (DeclinaxT.M.). Current Therapeutic Research, 6: 299.

Murmann W. Almirante L. Saccani-Guelfi M. (1966). Central nervous system effects of four B-adrenergic receptor blocking agents. Journal of Pharmacy and Pharmacology 18: 317.

Naylor W. G. Price J. M. Stone J. Lowe T. E. (1969). Further observations on the cardiovascular effects of ST 155 (Catapres). Journal of Pharmacology and Experimental Therapy, 166: 364.

Ng J. Phelan E. L. McGregor D. D. Laverty R. Taylor K. M. Smirk Horace Sir (1967). Properties of Catapres, a new hypotensive drug: a preliminary report. New Zealand Medical Journal, 66: 864.

Oates J. A. Seligmann A. W. Clark M. A. Rousseau P. Lee R. E. (1965). The relative efficiency of guanethidine, methyldopa and pargyline as antihypertensive agents. New England, Journal of Medicine, 273: 729.

Osnesti G. Schwartz A. B. Kim K. E. Swartz C. Brest A. N. (1969). Pharmacodynamic effects of a new antihypertensive drug, Catapres (ST-155). Circulation, 39: 219.

Paykel E. S. (1966). Hallucinosis on combined methyldopa and pargyline. British Medical Journal, 1: 803.

Prichard B. N. C. Gillam P. M. S. (1969). Treatment of hypertension with propranolol. British Medical Journal, 1: 7.

Prichard B. N. C. Johnston A. W. Hill I.D. Rosenheim M. L. (1968). Bethanidine, guanethidine, and methyldopa in treatment of hypertension: a within patient comparison. British Medical Journal, 1: 135.

Raftos J. (1969). The use of ‘Catapres’ in the treatment of severe hypertension. Medical Journal of Australia, 2: 684.

Rosenthal S. H. (1968). Recognition of depression. Geriatrics, 23: 111.

Schlittler E. Bein H. J. (1967). Rauwolfia alkaloids, in Antihypertensive Agents (ed. Schlittler E. ). Academic Press, New York. p. 191.

Schoepke H. G. Swett L. R. (1967). Chemistry and pharmacology of monoamine oxidadase inhibitors, in Antihypertensive Agents (ed. Schlittler E. ) Academic Press, New York. p. 393.

Seedat Y. K. Vawda E. I. Mitha S. Ramasar R. (1970). A comparison of alpha-methyl-dopa (Aldomet) and ST 155 (Catapres) in the treatment of hypertension. South African Medical Journal, 44: 300.

Simpson F. O. (1970). Combination antihypertensive therapy. Cardiovascular Clinics, 2(3): 38.

Simpson F. O. (1972). Management of the individual hypertensive patient. Medical Journal of Australia, special supplement, 2: 52.

Simpson F. O. Hodge J. V. (1967). Use of antihypertensive drugs in combinations, in Antihypertensive Agents (ed. Schlittler E. ). Academic Press, New York, p. 459.

Simpson F. O. Waal-Manning Hendrika J. (1971). Hypertension and depression: interrelated problems in therapy. Journal of the Royal College of Physicians, London, 6: 14.

Smirk Horace Sir (1963). Hypotensive action of methyldopa. British Medical Journal, 1: 146.

Sourkes T. L. (1965). The action of — methyldopa in the brain. British Medical Bulletin, 21: 66.

Trinker F. R. Barnett A. J. (1970). Trial of a new hypotensive drug — Clonidine (“Catapres”). Medical Journal of Australia. 2: 675.

Waal H. J. (1967). Propranolol-induced depression. British Medical Journal, 2: 50.

White A. G. (1965). Methyldopa and amitriptyline. Lancet, 2: 441.